Genentech, Inc. http://www.alacrastore.com/company-snapshot/Genentech_Inc-1006884 Thursday, July 24, 2008 3:23:46 PM 1006884 Genentech, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/BW-0001-26864262newstex/BW-0001-26864262xml Jul. ##, #### (Business Wire) -- Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its second quarter...0400000004016000040160480401601807000000070010000700100407014000070140087/23/2008 11:19:12 AM180000001800800018004000Business WireBW-0001-26864262CURIS INCGENENTECH INCDANIEL R PASSERICRISDNANewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-26865135newstex/BW-0001-26865135xml Jul. ##, #### (Business Wire) -- ## July ####: Fitch Ratings has today placed Roche Holding Ltd.'s (Roche) 'AA' Long-term Issuer Default Rating (IDR) and 'F#+' Short-term IDR on Rating Watch Negative. The rating action arose from the...04000000040160000401600504009000040090010200000002002000020020067/23/2008 11:19:12 AM18000000180160001802400018009000Business WireBW-0001-26865135GENENTECH INCDNANewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-26853364newstex/PRN-0001-26853364xml BASEL, Switzerland and TORONTO, Jul. ##, #### (Canada NewsWire Group delivered by Newstex) -- /CNW/ -- Roche (SWX: ROG) and ARIUS Research Inc. (TSX:ARI) today announced that the two companies have signed a definitive agreement for...070000000700500007003000070030010701400007014008070140120700100007001004040000000401600004016005040020000400200604009000040090021300000013010000130100057/23/2008 2:16:49 AM1800000018016000180200001801000019000000190020001900200719002018Canada NewsWire GroupPRN-0001-26853364ARI NETWORK SERVICES INCARIUS RESEARCH INCGENENTECH INCARIARISDNANewsNewstexhttp://www.alacrastore.com/storecontent/moodys/PR_159679_313350moodys/PR_159679_313350htmlGlobal Credit Research Rating Action ## JUL #### Rating Action: Genentech, Inc. Moody's reviews Genentech's A# for possible downgrade Approximately $# billion of rated long term debt affected. New York, July ##, #### -- Moody's Investors...7/23/2008 12:43:18 AMhtmlGenentech, Inc.Genentech, Inc.313350150.0000NewsRating ActionPR_159679_313350Credit & Investment ResearchMoody's Global Credit ResearchUS - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining ##.#% stake, or ###.### mil common shares, which it did not already own, in Genentech Inc, a biotechnology company, for $## in cash per share, or a total value of $##.### bil. The transaction was subject to customary closing conditions and shareholder approval.7/22/2008 6:51:14 PM77119M36871077119M77119MRoche Holding AGGenentech IncRoche Holding AGRoche Holding AGhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Roche_Holding_AG_intends_to_purchase_remaining_interest_in_Genentech_Inc-1997172020sdc/19971720201997172020Copyright © 2008, Thomson Financial, All Rights ReservedZurichDrugsSwitzerlandPharmaceutical preparations2834FFForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological researchDavis Polk & WardwellNew YorkDrugsUnited StatesBiological products, except diagnostic substances2836CACaliforniaPublicDNA121305001Mnfr pharm,med instrMnfr pharm,med instrCashCash OnlyCommon Stock2513006Jul 22 20080.000004505.000000.000004731.000003613.000002410.791001545.727000.0000013285.000000.305000.186005078.000002.880003080.000005011.0000012176.000000.0000019119.00000SFR31 Dec 070.0000011.360008622.789000.0000040753.5230067902.80900Swiss Franc30 Jun 0831 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.0000034.0000035.0000036.0000037.0000038.0000039.0000040.0000041.0000042.0000043.0000044.0000045.00000Roche Holding AG,headquartered in Basel,Switzerland, manufacturespharmaceuticals, medicines,diagnostics, chemicals,diagnostic kits, and medicalinstruments. The Group'sprincipal activities are todiscover, develop, manufactureand market novel health caresolutions. The Group operatesthrough two segments namelyPharmaceuticals andDiagnostics. ThePharmaceuticals divisionincludes prescription andmanufacturing ofpharmaceutical products. ThePharmaceutical segment hasthree sub-divisions namelyRoche Prescription, GenentechPrescription and ChugaiPrescription. Diagnosticsegment provides products andservices in all fields ofmedical testing. It alsoprovides reagents and testkits for molecular and cellbiology, analytical systemsand reagents for clinicalchemistry, immunochemistry,hematology and coagulation.Diagnostics division consistsof five business areas:Diabetes Care, Near PatientTesting, CentralizedDiagnostics, MolecularDiagnostics and AppliedScience. It operates inSwitzerland, European Union,United States, North America,Latin America, Japan, Asia,Africa, Australia and Oceania.The company was founded in1896.Roche Holding AG, headquartered in Basel, Switzerland,manufactures pharmaceuticals, medicines, diagnostics,chemicals, diagnostic kits, and medical instruments. TheGroup's principal activities are to discover, develop,manufacture and market novel health care solutions. TheGroup operates through two segments namely Pharmaceuticalsand Diagnostics. The Pharmaceuticals division includesprescription and manufacturing of pharmaceutical products.The Pharmaceutical segment has three sub-divisions namelyRoche Prescription, Genentech Prescription and ChugaiPrescription. Diagnostic segment provides products andservices in all fields of medical testing. It also providesreagents and test kits for molecular and cell biology,analytical systems and reagents for clinical chemistry,immunochemistry, hematology and coagulation. Diagnosticsdivision consists of five business areas: Diabetes Care,Near Patient Testing, Centralized Diagnostics, MolecularDiagnostics and Applied Science. It operates in Switzerland,European Union, United States, North America, Latin America,Japan, Asia, Africa, Australia and Oceania. The company wasfounded in 1896.Roche Holding AG, headquartered in Basel, Switzerland, manufactures pharmaceuticals, medicines, diagnostics, chemicals, diagnostic kits, and medical instruments. The Group's principal activities are to discover, develop, manufacture and market novel health care solutions. The Group operates through two segments namely Pharmaceuticals and Diagnostics. The Pharmaceuticals division includes prescription and manufacturing of pharmaceutical products. The Pharmaceutical segment has three sub-divisions namely Roche Prescription, Genentech Prescription and Chugai Prescription. Diagnostic segment provides products and services in all fields of medical testing. It also provides reagents and test kits for molecular and cell biology, analytical systems and reagents for clinical chemistry, immunochemistry, hematology and coagulation. Diagnostics division consists of five business areas: Diabetes Care, Near Patient Testing, Centralized Diagnostics, Molecular Diagnostics and Applied Science. It operates in Switzerland, European Union, United States, North America, Latin America, Japan, Asia, Africa, Australia and Oceania. The company was founded in 1896.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.00000Genentech Inc, located inSouth San Francisco,California, is a biotechnologycompany that discovers,develops, manufactures andcommercializesbiotherapeutics. It marketsAvastin for treatingmetastatic cancer of the colonor rectum and metastaticnon-squamous non-small celllung cancer. The Company alsocommercialized Rituxan totreat B-cell non-Hodgkin'slymphoma, Herceptin fortreating node-positive breastcancer, Lucentis to treatneovascular age-relatedmacular degeneration, Xolairfor adults with asthma,Tarceva for the treatment ofmetastatic non-small cell lungcancer and Nutropin andNutropin AQ growth hormoneproducts. The company wasfounded in 1976.Genentech Inc, located in South San Francisco, California,is a biotechnology company that discovers, develops,manufactures and commercializes biotherapeutics. It marketsAvastin for treating metastatic cancer of the colon orrectum and metastatic non-squamous non-small cell lungcancer. The Company also commercialized Rituxan to treatB-cell non-Hodgkin's lymphoma, Herceptin for treatingnode-positive breast cancer, Lucentis to treat neovascularage-related macular degeneration, Xolair for adults withasthma, Tarceva for the treatment of metastatic non-smallcell lung cancer and Nutropin and Nutropin AQ growth hormoneproducts. The company was founded in 1976.Genentech Inc, located in South San Francisco, California, is a biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics. It markets Avastin for treating metastatic cancer of the colon or rectum and metastatic non-squamous non-small cell lung cancer. The Company also commercialized Rituxan to treat B-cell non-Hodgkin's lymphoma, Herceptin for treating node-positive breast cancer, Lucentis to treat neovascular age-related macular degeneration, Xolair for adults with asthma, Tarceva for the treatment of metastatic non-small cell lung cancer and Nutropin and Nutropin AQ growth hormone products. The company was founded in 1976.0.000000.000000.000001050.89000YU.S. Dollar21 Jul 08Mon, 21 Jul 2008 00:00:00 ESTDate Announced: 07/21/2008Date Effective:Acq. Rem. Int.Unsolic.0.000000.000000.00000-2030.000000.0000089.00000Price/Share0.0000041246.5 U.S. Dollar41246.4520093529.3690041246.5 U.S. Dollar41246.452000.000000.0000089.0000089.0000039216.4520041246.5 U.S. Dollar1.00000N20593.365000.000000.000000.000000.000000.0000041246.4520041246.452000.000000.00000-0.40000-0.65900-0.167005.8680055.9000044.100000.0000018.419007.0400030.367007.681008.6100030.367007.68100116544.6630081.8200075.3900074.1800040.087000.000000.157000.0000048.152000.000002475.0000077955.1520013285.0000026.246000.0000047.139000.0000019.980008.7800018.050001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.00000US - Roche Holding AG plannedto launch an unsolicitedtender offer to acquire theremaining 44.1% stake, or463.443 mil common shares,which it did not already own,in Genentech Inc, abiotechnology company, for $89in cash per share, or a totalvalue of $41.246 bil. Thetransaction was subject tocustomary closing conditionsand shareholder approval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining 44.1% stake, or 463.443 mil common shares, which it did not already own, in Genentech Inc, a biotechnology company, for $89 in cash per share, or a total value of $41.246 bil. The transaction was subject to customary closing conditions and shareholder approval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire theremaining 44.1% stake, or 463.443 mil common shares, which it did not already own, inGenentech Inc, a biotechnology company, for $89 in cash per share, or a total value of$41.246 bil. The transaction was subject to customary closing conditions and shareholderapproval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining 44.1% stake, or 463.443 mil common shares, which it did not already own, in Genentech Inc, a biotechnologycompany, for $89 in cash per share, or a total value of $41.246 bil. The transaction was subject to customary closing conditions and shareholder approval.US - Roche Holding AG planned to launch an unsolicited tender offer to acquire the remaining 44.1% stake, or 463.443 mil common shares,which it did not already own, in Genentech Inc, a biotechnology company, for $89 in cash per share, or a total value of $41.246 bil. Thetransaction was subject to customary closing conditions and shareholder approval.$ 41,246.452 - Greenhill & Co, LLC - Adv0.00000Greenhill & Co, LLC1.00000Intended53307.000009761.0000046133.0000076866.0000012.642000.000004731.000003613.000002410.791001545.727000.0000013285.000005078.000002.590000.000001.180000.730000.000002.8800013285.0000011905.000000.000007469.584006782.190000.000002769.000002113.000001278.99100784.816000.000003080.000004426.000003403.000002012.849001219.416000.000005011.0000011724.000009284.000006633.372004621.157000.0000012176.0000019119.0000018940.000000.0000012000.969009383.054000.00000Status:IntendedUS30.9030030.9030.412007.040007.04048.286000.0000023.1840032.945000.0000013285.0000025.627000.000000.0000018.419007.040002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations121305001ZurichSwitzerland2834ForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research121305001ZurichSwitzerland2834ForeignPublicROG41246.4520041246.4520041246.4520020593.36500Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/newstex/PZM-0001-26840183newstex/PZM-0001-26840183xml CAMBRIDGE, Mass., Jul. ##, #### (July delivered by Newstex) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the appointment of two new members to its Board...0700000007005000090000000901500004000000040020000400200604016000040160080701400007014012070030000700300107001000070010041300000013010000130100057/22/2008 1:22:53 PM1800000018007000190000001900200019002007PrimeNewswirePZM-0001-26840183GENENTECH INCINFINITY PHARMACEUTICALS INC.LILLY ELI & COMartin BablerDNAINFILLYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/ACT-0001-26804121newstex/ACT-0001-26804121xml Jul. ##, #### (Action Economics delivered by Newstex) -- U.S. equities are trading positively again following BofA earnings results, which came in above low expectations, despite posting a ##% decline in Q# net income and $#.# bln...0400000004006000040060020401600004016048040160187/21/2008 11:23:48 AM180000001800400018008000Action Economics AlertsACT-0001-26804121CITIGROUP INCGENENTECH INCMICROSOFT CORPYAHOO INCCDNAMSFTYHOONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26794180newstex/PRN-0005-26794180xml BASEL, Switzerland, Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY), a world-leading healthcare company, announced today that it has proposed to acquire the outstanding publicly held...070000000700500009000000090150000901600004000000040020000400200604016000040160050401600804016047040060000400600504009000040090020401000004010006070140000701401207014008070030000700300113000000130100001301000513002000130020050200000002002000020020067/21/2008 1:19:05 AM1800000018016000180200001801000019000000190020001900201319002007190020181900100019001005PR Newswire USPRN-0005-26794180GENENTECH INCARTHUR D LEVINSONDNANewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1805212ccbn/T1805212norm...Good afternoon, ladies and gentlemen. My name is Gerald and I will be your conference operator. At this time, I would like to welcome everyone to the Genentech Q# #### earnings conference call. (OPERATOR INSTRUCTIONS). It is now my pleasure to introduce your host, Ms. Kathee Littrell, Vice President of Investor Relations. Ms. Littrell, you may begin. ... 7/16/2008 4:55:29 PMGenentech, Inc.54.0000Q1 2008 Genentech, Inc. Earnings Conference CallDNA4:45PM ETTranscriptT1805212Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/B1805212ccbn/B1805212norm...YoverY growth resulted from increase sales in metastatic non-small cell lung cancer and metastatic breast cancer.... 7/16/2008 4:55:25 PMGenentech, Inc.54.0000Q1 2008 Genentech, Inc. Earnings Conference CallDNA4:45PM ETBriefB1805212Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/MCOM-0004-26675037newstex/MCOM-0004-26675037xml Jul. ##, #### (M# Communications Ltd. delivered by Newstex) -- Genentech Inc (NYSE: DNA), a biotechnology company, reported on ## July its financial results for the second quarter of ####. The company generated non-GAAP operating revenue...040000000401600004016018040160487/15/2008 12:19:37 PM180000001800400018008000M2 EquityBitesMCOM-0004-26675037GENENTECH INCDNANewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1884224ccbn/B1884224norm...Focused on challenges of successful commercial execution to drive penetration and share of key products, such as Avastin for breast cancer market. ... 7/14/2008 9:03:48 PMGenentech, Inc.106.0000EditedQ2 2008 Genentech, Inc. Earnings Conference Call SummaryDNA4:45pm ETBriefB1884224Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1884224ccbn/T1884224norm...Good afternoon, ladies and gentlemen. My name is Gerald, and I will be your conference operator. At this time I would like to welcome everyone to the Genentech second-quarter #### earnings conference. (OPERATOR INSTRUCTIONS). Thank you. It is now my pleasure to introduce your host, Ms. Kathee Littrell, Vice President of Investor Relations. Ms. Littrell, you may begin. ... 7/14/2008 8:05:48 PMGenentech, Inc.106.0000FinalQ2 2008 Genentech, Inc. Earnings Conference Call TranscriptDNA4:45pm ETTranscriptT1884224Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-26651908newstex/BW-0001-26651908xml Jul. ##, #### (Business Wire) -- Genentech, Inc. (NYSE: DNA) today announced financial results for the second quarter of ####. Key results for the second quarter of #### include: U.S. product sales of $#,### million, a # percent...09000000090160000700000007005000040000000401600004016048040160180401600104016003040160050400200004002006040020010401000004010006130000001301000013010005130020001300200507001000070010047/14/2008 5:17:29 PM1800000018004000180080001802000018023000180160001900000019001000Business WireBW-0001-26651908GENENTECH INCDNANewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26567987newstex/PRN-0005-26567987xml SHANGHAI, China, Jul. ##, #### (Xinhua-PRNewswire delivered by Newstex) -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China...0400000004006000090000000901500013000000130020001300200513010000130100050400200004002006040160000401600807000000070140000701401207003000070030017/10/2008 9:24:25 AM180000001802000018007000190000001900100019002000190020091900201319002004PR Newswire USPRN-0005-26567987CITY CAPITAL CORPGENENTECH INCMORGAN STANLEYPFIZER INCCTCCDNAMSPFENewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-26253651newstex/PRN-0001-26253651xml VANCOUVER, Jun. ##, #### (Canada NewsWire Group delivered by Newstex) -- /CNW/ -- Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that it has entered into an agreement granting rights to Roche Diagnostics to...1100000011002000130000001300200013002005130010001300100204000000040090000400900204002000040020060400600004006005070000000701400007014009070140126/26/2008 9:26:27 AM18000000180200001802200018010000180040001900000019001000Canada NewsWire GroupPRN-0001-262536513M COGENENTECH INCRESPONSE BIOMEDICAL CORPDNAMMMRBMRPBIFNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1877843ccbn/T1877843norm...I'm pleased today to be able to introduce two members of the Genentech management team, Sue Morris from Investor Relations, and the company's Chief Financial Officer, David Ebersman. David, welcome back. I'm glad to have you here. And it's always refreshing to get David's perspective, as he's been at Genentech for ## years across a number of different functional areas. So, we appreciate you being here, and welcome. ... 6/18/2008 6:04:00 PMGenentech, Inc.54.0000FinalGenentech, Inc. at William Blair & Company Growth Stock Conference TranscriptDNA9:10am CTTranscriptT1877843Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1871988ccbn/T1871988norm... - Goldman Sachs - Analyst[We will be beginning] this discussion with Genentech, which is the largest biotech company. And we are really fortunate this morning to have Dr. Susan Hellmann, who is the President for Product Development. I think Sue has been there for about ## years. She is an oncologist, and I guess in the last ## years, the Company has become the number one oncology company. And I think a lot of you are familiar with what she has done. And in the last -- I think, five or six years, actually, she has been voted the top ## most powerful women in business by Fortune. So, congratulations. And also on the podium is Dr. Kathee Littrell, who is the Head of Investor Relations. They will be answering questions after the presentation. Thank you very much, Sue. ... 6/11/2008 7:05:00 PMGenentech, Inc.54.0000FinalGenentech, Inc. at Goldman Sachs Healthcare Conference TranscriptDNA10:40am PTTranscriptT1871988Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-25920784newstex/BW-0001-25920784xml Jun. ##, #### (Business Wire) -- Genentech, Inc. (NYSE: DNA) announced today that it has settled its patent litigation with MedImmune, Inc. involving the Cabilly patent (U.S. Patent No. #,###,###), which is co-owned by Genentech and...02000000020020000200200402002007020020060400000004016000040160316/11/2008 5:15:53 PM180000001801400018018000Business WireBW-0001-25920784GENENTECH INCDNANewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1846289ccbn/T1846289norm...Good afternoon, ladies and gentlemen. Welcome to the Genentech ASCO data discovery conference call. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there will be a question and answer session. (OPERATOR INSTRUCTIONS) Thank you. I would now like to turn the conference over to your management team. ... 6/3/2008 2:05:00 AMGenentech, Inc.54.0000FinalGenentech, Inc. at ASCO 2008 Annual Meeting TranscriptDNA6:00pm CTTranscriptT1846289Credit & Investment ResearchThomson Street Events